Two guidances on next-generation sequencing map out approaches for NGS developers to bring their product to market by relying on established standards and databases rather than new clinical studies to validate individual markers.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?